Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis

This study has been completed.
Sponsor:
Information provided by:
Biolipox AB
ClinicalTrials.gov Identifier:
NCT00533637
First received: September 20, 2007
Last updated: February 29, 2008
Last verified: September 2007

September 20, 2007
February 29, 2008
September 2007
Not Provided
  • Taste perversion scores [ Time Frame: 7 days ]
  • Local tolerance scores [ Time Frame: 7 days ]
Same as current
Complete list of historical versions of study NCT00533637 on ClinicalTrials.gov Archive Site
  • Treatment efficacy [ Time Frame: 1 days ]
  • Type and incidence of AEs [ Time Frame: 7 days ]
Same as current
Not Provided
Not Provided
 
Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis
A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis

Evaluation of NLA Nasal Spray with regard to taste perversion and local tolerance

Oral or intranasal antihistamines is the first line treatment for allergic rhinitis. Cetirizine is a second-generation selective antihistamine widely used in an oral formulation for the treatment of allergic rhinitis. Local administration of cetirizine has been shown to reduce symptoms after allergen challenge, and has the potential to shorten the time to onset and decrease systemic side effects. However, local irritation and nasal burning/pain has been reported after nasal administration. For the compliance of the patients taking a nasal spray, the taste and tolerance of the product is of particular importance. NLA Nasal Spray contains cetirizine in a liposomal formulation aiming to improve the tolerability. The present study aims to compare the NLA Nasal Spray with cetirizine in an aqueous formulation and placebo with regard to taste perversion and local tolerance. This will be investigated off-season in patients with seasonal allergic rhinitis after provocation with allergen.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Allergic Rhinitis
  • Drug: Cetirizine dihydrochloride (10 mg/ml) liposomal formulation
    2x110μL in each nostril twice daily for 7 days
  • Drug: Cetirizine dihydrochloride (10 mg/ml) buffer solution
    2x110μL in each nostril, as a single dose
  • Drug: Placebo
    Citrate buffer with preservatives
  • Experimental: 1
    NLA Nasal Spray
    Intervention: Drug: Cetirizine dihydrochloride (10 mg/ml) liposomal formulation
  • Active Comparator: 2
    Intervention: Drug: Cetirizine dihydrochloride (10 mg/ml) buffer solution
  • Placebo Comparator: 3
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
December 2007
Not Provided

Inclusion Criteria:

  • 18 to 50 years of age (inclusive)
  • Body Mass Index (BMI) between 18 and 28 kg/m2
  • History of pollen-induced seasonal allergic rhinitis for at least two years and otherwise healthy
  • Elevated specific IgE to at least one aero allergen or at least one positive skin pick test (SPT)
  • Seasonal allergic rhinitis with symptoms provoked by the allergen with a corresponding elevated specific IgE or positive SPT
  • Signed written Informed Consent

Exclusion Criteria:

  • Perennial allergic rhinitis except for cat and/or dog sensitivity under the condition that these patients are not exposed to cats and dogs
  • Soy bean allergy
  • Peanut allergy
  • Smoking during the last month before study inclusion
  • Any upper respiratory tract infection during the period of 2 weeks before the start of the study
  • Chronic medication
  • Any medication, including herbal medicines, during their last five half-lives (t½)
  • Nasal anatomical deviations
  • Extensive use of nasal sprays as judged by the Investigator
  • Ongoing nasal symptoms as judged by the Investigator
  • Known hypersensitivity to cetirizine
  • Pregnant or breast-feeding women
  • Fertile women not using reliable methods of contraception (i.e. IUD, barrier method, hormonal contraceptives, abstinence)
  • Participation in any other investigational study in the last three months
  • Inability to adhere to the study plan
  • Previous inclusion in this study
  • Blood donation during the last three months
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00533637
NLA-C004P
No
Not Provided
Biolipox AB
Not Provided
Principal Investigator: Lennart Greiff, MD, PhD University of Lund
Biolipox AB
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP